As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
The 19th Human Proteome Organization World Congress will be held from the 18th through 22nd of October, in innovative Stockholm, Sweden. Bringing together biopharma and biotech drug developments with a theme of ‘Clinical Proteomics for the Benefit of Patients’, this will be the first time involving Pharma industry in one of the foremost arena for the advancements of life sciences. To learn more and register for the congress, please visit the official website.
The concept of antibody microarrays is one of the most versatile approaches within multiplexed immunoassay technologies. These types of arrays have increasingly become an attractive tool for the exploratory detection and study of protein abundance, function, pathways, and potential drug targets. In spite of the growing number of studies utilizing this technique, few reviews about antibody microarray technology have been presented to reflect the quality and future uses of the generated data. In this review, we provide a summary of the recent applications of antibody microarray techniques in basic biology and clinical studies, providing insights into the current trends and future of protein analysis.
In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Make a suggestion here
Aims and scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Guest edited by Vera Ignjavtovic, Allen Everett and Hanno Steen
The Paediatric Proteomics (PediOme) is an initiative of HUPO that aims to advance the use of proteomic techniques to solve major issues in Paediatric medicine.
Proteomics in India
Guest edited by Harsha Gowda and Akhilesh Pandey
This collections features the latest advances in Proteomics research from India.
Glycoproteomics and glycomics
Guest edited by Punit Shah and Hui Zhang
This thematic series publishes both solicited and unsolicited content on the topic of protein glycosylation; one of the most common protein modifications in both normal biological processes and diseases. This series focuses on glycoproteomic or glycomic methods and their clinical applications.
Clinical Proteomics is affiliated with the Human Proteome Organization (HUPO). HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
- Editorial Board
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
80 days to first decision for reviewed manuscripts only
68 days to first decision for all manuscripts
150 days from submission to acceptance
11 days from acceptance to publication
83 Altmetric mentions